Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

Imaging of Resting State Functional Connectivity Following Transcranial Magnetic Stimulation

Clinical Trial Details

In our previous work, we have developed bio-markers from brain images of transcranial magnetic stimulation (TMS) treatment for depression. 

The goal of the current study is to build on this past work by looking at the immediate neural effects of a single session of several forms of TMS, previously established to be effective and safe. 

The findings of this study will help figure out the best TMS targets and forms of treatment in future intervention studies. Data from the current pilot trial will also inform future efforts to effectively match a TMS treatment method to each individual, based on this individual's brain patterns. 

Key Eligibility: 

Inclusion Criteria

  • Age 18 to 70
  • Fluent in English
  • Meet DSM-V criteria for a diagnosis of major depressive disorder, bipolar 1 disorder, bipolar 2 disorder or an anxiety disorder. Subjects with depression or anxiety symptoms who do not meet criteria for one of these disorders will be eligible if they present with a minimum score of 8 or higher on the Beck Anxiety Inventory or Beck Depression Inventory as assessed in an initial screening interview.

Exclusion Criteria

  • History of seizure disorder, stroke, brain surgery, metal implants (including braces, orthopedic implant, cochlear implant, implanted cardiac pacemaker, implanted cardioverter defibrillator, and ocular implant)
  • Parkinson's disease
  • Any form of dementia
  • Any form of head injury resulting in loss of consciousness
  • Claustrophobia
  • Weight over 250 pounds (owing to the size of the MR scanner bore)
  • Women who are currently pregnant or breastfeeding. Subjects who indicate that there is a chance that they may be pregnant will be asked to take a pregnancy test. They will be informed of the potential for false positive results due to diet, vitamins, and supplements, or over-the-counter medications. A positive pregnancy test will necessitate exclusion from the study, and the results will be disclosed to the participant.
  • Active suicidal ideation
  • Co-morbid substance use disorder within the last 12 months
  • Currently psychotic, manic, or hypomanic N.B. For symptomatic participants, psychiatric comorbidities other than the listed above will be eligible for inclusion, as long as none of the exclusion criteria above are present. For healthy participants, a diagnoseable psychiatric condition will be grounds for exclusion

Study contact by location

Upper East Side - Manhattan


Katharine Dunlop

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:



Open to Enrollment

Age Group